177 related articles for article (PubMed ID: 38229348)
1. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials.
Tarn JR; Howard-Tripp N; Lendrem DW; Mariette X; Saraux A; Devauchelle-Pensec V; Seror R; Skelton AJ; James K; McMeekin P; Al-Ali S; Hackett KL; Lendrem BC; Hargreaves B; Casement J; Mitchell S; Bowman SJ; Price E; Pease CT; Emery P; Lanyon P; Hunter J; Gupta M; Bombardieri M; Sutcliffe N; Pitzalis C; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Griffiths B; Johnsen SJA; Norheim KB; Omdal R; Stocken D; Everett C; Fernandez C; ; Isaacs JD; Gottenberg JE; ; Ng WF;
Lancet Rheumatol; 2019 Oct; 1(2):e85-e94. PubMed ID: 38229348
[TBL] [Abstract][Full Text] [Related]
2. Comorbidities in the UK Primary Sjögren's Syndrome Registry.
Tarn J; Lendrem D; Barnes M; Casement J; Ng WF
Front Immunol; 2022; 13():864448. PubMed ID: 35603172
[TBL] [Abstract][Full Text] [Related]
3. Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine.
Collins A; Lendrem D; Wason J; Tarn J; Howard-Tripp N; Bodewes I; Versnel MA; Gottenberg JE; Seror R; Mariette X; Ng WF
Rheumatol Int; 2021 Sep; 41(9):1593-1600. PubMed ID: 34165604
[TBL] [Abstract][Full Text] [Related]
4. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts.
Nguyen Y; Nocturne G; Henry J; Ng WF; Belkhir R; Desmoulins F; Bergé E; Morel J; Perdriger A; Dernis E; Devauchelle-Pensec V; Sène D; Dieudé P; Couderc M; Fauchais AL; Larroche C; Vittecoq O; Salliot C; Hachulla E; Le Guern V; Gottenberg JE; Mariette X; Seror R
Lancet Rheumatol; 2024 Apr; 6(4):e216-e225. PubMed ID: 38437852
[TBL] [Abstract][Full Text] [Related]
5. Symptom-Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance.
McCoy SS; Woodham M; Bartels CM; Saldanha IJ; Bunya VY; Maerz N; Akpek EK; Makara MA; Baer AN
Arthritis Rheumatol; 2022 Sep; 74(9):1569-1579. PubMed ID: 35594474
[TBL] [Abstract][Full Text] [Related]
6. Discriminative power of salivary gland ultrasound in relation to symptom-based endotypes in suspected and definite primary Sjögren's Syndrome.
Deroo L; Achten H; De Boeck K; Genbrugge E; Bauters W; Roels D; Dochy F; Creytens D; De Craemer AS; Van den Bosch F; Elewaut D; Peene I
Semin Arthritis Rheum; 2022 Oct; 56():152075. PubMed ID: 35907342
[TBL] [Abstract][Full Text] [Related]
7. The Florida Scoring System for stratifying children with suspected Sjögren's disease: a cross-sectional machine learning study.
Zeng W; Thatayatikom A; Winn N; Lovelace TC; Bhattacharyya I; Schrepfer T; Shah A; Gonik R; Benos PV; Cha S
Lancet Rheumatol; 2024 May; 6(5):e279-e290. PubMed ID: 38658114
[TBL] [Abstract][Full Text] [Related]
8. Sjögren's and non-Sjögren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature.
Pucino V; Turner JD; Nayar S; Kollert F; Rauz S; Richards A; Higham J; Poveda-Gallego A; Bowman SJ; Barone F; Fisher BA
RMD Open; 2022 May; 8(1):. PubMed ID: 35589331
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
[TBL] [Abstract][Full Text] [Related]
10. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
[TBL] [Abstract][Full Text] [Related]
11. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure.
Arends S; de Wolff L; van Nimwegen JF; Verstappen GMPJ; Vehof J; Bombardieri M; Bowman SJ; Pontarini E; Baer AN; Nys M; Gottenberg JE; Felten R; Ray N; Vissink A; Kroese FGM; Bootsma H
Lancet Rheumatol; 2021 Aug; 3(8):e553-e562. PubMed ID: 38287621
[TBL] [Abstract][Full Text] [Related]
12. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
Bowman SJ; Everett CC; O'Dwyer JL; Emery P; Pitzalis C; Ng WF; Pease CT; Price EJ; Sutcliffe N; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Reynolds C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Giles IP; Sharples LD; Bombardieri M
Arthritis Rheumatol; 2017 Jul; 69(7):1440-1450. PubMed ID: 28296257
[TBL] [Abstract][Full Text] [Related]
13. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sjögren's syndrome differ in molecular signatures and treatment perspectives.
Idborg H; Zandian A; Sandberg AS; Nilsson B; Elvin K; Truedsson L; Sohrabian A; Rönnelid J; Mo J; Grosso G; Kvarnström M; Gunnarsson I; Lehtiö J; Nilsson P; Svenungsson E; Jakobsson PJ
Arthritis Res Ther; 2019 Feb; 21(1):62. PubMed ID: 30777133
[TBL] [Abstract][Full Text] [Related]
14. Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea.
Park Y; Lee J; Koh JH; Sung YK; Lee SS; Choe JY; Shim SC; Kim JM; Kwon SR; Kim HO; Chung SH; Park SH; Kwok SK
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):107-113. PubMed ID: 31376264
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study.
de Frémont GM; Costedoat-Chalumeau N; Lazaro E; Belkhir R; Guettrot-Imbert G; Morel N; Nocturne G; Molto A; Goulenok T; Diot E; Perard L; Ferreira-Maldent N; Le Besnerais M; Limal N; Martis N; Abisror N; Debouverie O; Richez C; Sobanski V; Maurier F; Sauvetre G; Levesque H; Timsit MA; Tieulié N; Orquevaux P; Bienvenu B; Mahevas M; Papo T; Lartigau-Roussin C; Chauvet E; Berthoux E; Sarrot-Reynauld F; Raffray L; Couderc M; Silva NM; Jourde-Chiche N; Belhomme N; Thomas T; Poindron V; Queyrel-Moranne V; Delforge J; Le Ray C; Pannier E; Mariette X; Le Guern V; Seror R;
Lancet Rheumatol; 2023 Jun; 5(6):e330-e340. PubMed ID: 38251600
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
[TBL] [Abstract][Full Text] [Related]
18. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome.
Traianos EY; Locke J; Lendrem D; Bowman S; Hargreaves B; Macrae V; ; Tarn JR; Ng WF
Rheumatol Int; 2020 Apr; 40(4):541-548. PubMed ID: 32047959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
